News & Events
2020-12-08
SYNCELL Team Won the 17th Taiwan National Innovation Award

SYNCELL today announced that the company’s Microscoop Technology has won the 17th Taiwan National Innovation Award. The National Innovation Award is considered one of the most important indicators in recognizing outstanding research & development achievements as well as innovations from healthcare institutions and enterprises in the biotech industry of Taiwan.

After multiple runs of rigorous reviews by Research Center for Biotechnology and Medicine Policy (RBMP) expert reviewers, SYNCELL was chosen as the winner of Specialized Materials and Applied Biotechniques. During the award ceremony on December 8, 2020, SYNCELL and five other winning teams each made a Showcase Pitch to a large audience comprised of private investors, corporate venture groups, and representatives from leading science and technology companies to seek new capitals and explore strategic collaboration and partnership opportunity.

During his presentation, the leader of the SYNCELL team, Dr. Jung-Chi Liao, explained the principle of the breakthrough Microscoop™ technology and how the system can turn a high-content microscope into a novel spatial proteomics tool that can harvest cellular and subcellular components from selected regions. By design, the technology is capable of identifying critical proteins in situ whose biological functions were unknown to researchers before.

The technology has attracted high interests from many domestic and international researchers and the company plans to start selling beta units in Q4 2021.

Link Jung-Chi Liao’s demo pitch

（圖）

About SYNCELL INC.
SYNCELL is a development stage company with a vision to revolutionize in situ cell biology and biomedical research. The company will soon introduce its groundbreaking Microscoop™ platform, the first and only system that allows users to pick up, identify and quantify thousands of known and unknown proteins in specified cellular and subcellular locations. Microscoop™ is pairing unique imaging and illuminating capabilities with novel photolabeling chemicals to provide deep spatial proteomics insights to transform a wide range of basic biology and translational research including neuroscience, oncology, immunology, infectious disease, gene therapy, and to identify novel therapeutic targets with spatial context to accelerate drug discovery and development programs.

CONTACT:
Shu-Yi Liao
SYNCELL INC.
Phone +886-2-77505632
Info@syncell.com
Follow SYNCELL on LinkedIn at SYNCELL INC. and tag your posts with #syncell or #microscoop

2020-12-08
SYNCELL Team Won the 17th Taiwan National Innovation Award

SYNCELL today announced that the company’s Microscoop Technology has won the 17th Taiwan National Innovation Award. The National Innovation Award is considered one of the most important indicators in recognizing outstanding research & development achievements as well as innovations from healthcare institutions and enterprises in the biotech industry of Taiwan.

After multiple runs of rigorous reviews by Research Center for Biotechnology and Medicine Policy (RBMP) expert reviewers, SYNCELL was chosen as the winner of Specialized Materials and Applied Biotechniques. During the award ceremony on December 8, 2020, SYNCELL and five other winning teams each made a Showcase Pitch to a large audience comprised of private investors, corporate venture groups, and representatives from leading science and technology companies to seek new capitals and explore strategic collaboration and partnership opportunity.

During his presentation, the leader of the SYNCELL team, Dr. Jung-Chi Liao, explained the principle of the breakthrough Microscoop™ technology and how the system can turn a high-content microscope into a novel spatial proteomics tool that can harvest cellular and subcellular components from selected regions. By design, the technology is capable of identifying critical proteins in situ whose biological functions were unknown to researchers before.

The technology has attracted high interests from many domestic and international researchers and the company plans to start selling beta units in Q4 2021.

Link Jung-Chi Liao’s demo pitch

（圖）

About SYNCELL INC.
SYNCELL is a development stage company with a vision to revolutionize in situ cell biology and biomedical research. The company will soon introduce its groundbreaking Microscoop™ platform, the first and only system that allows users to pick up, identify and quantify thousands of known and unknown proteins in specified cellular and subcellular locations. Microscoop™ is pairing unique imaging and illuminating capabilities with novel photolabeling chemicals to provide deep spatial proteomics insights to transform a wide range of basic biology and translational research including neuroscience, oncology, immunology, infectious disease, gene therapy, and to identify novel therapeutic targets with spatial context to accelerate drug discovery and development programs.

CONTACT:
Shu-Yi Liao
SYNCELL INC.
Phone +886-2-77505632
Info@syncell.com
Follow SYNCELL on LinkedIn at SYNCELL INC. and tag your posts with #syncell or #microscoop